Ausperbio
ausperbio.com
Actively hiring
Biologics & Biosimilars
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$256M
3 rounds on record
Latest round
$120M
Series C · Aug 2026 · 1 mo ago
Backers
2
RA Capital Management, Qiming Venture Partners
The money's age
Fresh money
1 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 27
Raised a round Series C $120M
Sep 23, 2025
Raised a round Venture round $63M · Pulse 2.0
Dec 25, 2024
Raised a round Series B $73M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series C | Aug 2026 | $120M | — | morningstar.com |
| Venture round | Sep 2025 | $63M | — | Pulse 2.0 |
| Series B | Dec 2024 | $73M | — | medindia.net |
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
Qiming Venture Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company.
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
CAMPfield Therapeutics is a clinical-stage biopharmaceutical company developing prifemilast, a once-daily oral PDE4B-selective inhibitor…
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The…
Nuance Pharma are an innovation focused biopharmaceutical company, with both late-stage clinical pipeline and commercial stage asset…
Overview
AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming HBV treatment for cure and advancing oligonucleotide therapeutics.
News
AusperBio Raises $120 Million Series C As Total Funding Reaches $360 Million And AHB-137 Advances Through Phase 3
AusperBio has closed a $120 million Series C financing to advance its chronic hepatitis B pipeline, including the Phase 3 registrational program and potential commercialization of its lead investigational therapy AHB-137. The financing brings AusperBio's
Read more
Report
AusperBio raises $120m to progress hepatitis B therapies
AusperBio's total capital raised since 2024 has reached $360m.
Read more
Report
AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies
Read more
Report
AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171
/PRNewswire/ -- AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a near-commercial Biopharmaceutical company focused on...
Read more
Report
AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
/PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted...
Read more
Report
AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy Newswise
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oligonucleotide-based therapies for functional cure of chronic hepatitis B (CHB), today announced full end-of-follow-up (EO
Read more
Report
AusperBio: $63 Million Closed For Advancing Targeted Oligonucleotide Therapies
AusperBio, a biotechnology company focused on curing chronic hepatitis B, has announced it raised $63 million in Series B2 funding. This new investment adds to the strong financial backing the company has already received and reflects growing confidence i
Read more
Report
AusperBio Secures $73 Million in Series B Financing to Advance Functional Cure for Chronic Hepatitis B
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a privately held clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Foster City
United States
Regional office
Our Use of Cookies
950 Tower Lane, Suite 340, Foster City, CA 94404, USA